Spero Therapeutics, Inc. (SPRO)
1.20
+0.06
(+5.26%)
USD |
NASDAQ |
Oct 09, 16:00
1.20
0.00 (0.00%)
After-Hours: 20:00
Spero Therapeutics Cash from Operations (Quarterly) : -5.355M for June 30, 2026
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -5.355M |
| March 31, 2026 | 15.86M |
| December 31, 2025 | -8.351M |
| September 30, 2025 | 17.42M |
| June 30, 2025 | -17.69M |
| March 31, 2025 | -4.002M |
| December 31, 2024 | -23.40M |
| September 30, 2024 | 12.76M |
| June 30, 2024 | -18.74M |
| March 31, 2024 | 5.938M |
| December 31, 2023 | -17.49M |
| September 30, 2023 | 15.92M |
| June 30, 2023 | -18.56M |
| March 31, 2023 | -12.85M |
| December 31, 2022 | 44.48M |
| September 30, 2022 | -0.957M |
| June 30, 2022 | -23.03M |
| March 31, 2022 | -28.22M |
| Date | Value |
|---|---|
| December 31, 2021 | -27.35M |
| September 30, 2021 | -4.952M |
| June 30, 2021 | -16.57M |
| March 31, 2021 | -15.48M |
| December 31, 2020 | -16.38M |
| September 30, 2020 | -21.26M |
| June 30, 2020 | -24.90M |
| March 31, 2020 | -23.33M |
| December 31, 2019 | -17.37M |
| September 30, 2019 | -9.659M |
| June 30, 2019 | -12.07M |
| March 31, 2019 | -10.92M |
| December 31, 2018 | -13.51M |
| September 30, 2018 | -5.514M |
| June 30, 2018 | -8.641M |
| March 31, 2018 | -11.96M |
| December 31, 2017 | -12.74M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Inovio Pharmaceuticals, Inc. | -18.05M |
| Fortress Biotech, Inc. | -59.28M |
| Kura Oncology, Inc. | -62.55M |
| ACADIA Pharmaceuticals, Inc. | 100.78M |
| Alnylam Pharmaceuticals, Inc. | 326.72M |
Cash from Operations (Quarterly) Related Metrics
| Free Cash Flow | 19.58M |
| Free Cash Flow Per Share (Quarterly) | -0.0924 |
| Free Cash Flow to Equity (Quarterly) | -4.924M |
| Free Cash Flow to Firm (Quarterly) | -5.355M |
| Free Cash Flow Yield | 28.27% |